Skip to main content

Table 2 Calculations of sequence ratios incorporating co-medication for the prescribing cascade of three cardiovascular medication groups-induced erectile dysfunction and patients using multiple groups

From: Prescription Sequence Symmetry Analysis (PSSA) to assess prescribing cascades: a step-by-step guide

 

Study population

Patients using index before marker

Patients using marker before index

cSR

SRnull

aSR (95% CI)

Any ACEi usersa

3,188

2,152

1,036

2.08

1.09

1.91 (1.84-1.99)

Sole ACEi usersb

1,170

767

403

1.90

1.09

1.74 (1.62-1.86)

Any beta blocker users

3,035

1,937

1,098

1.76

1.06

1.66 (1.58-1.73)

Sole beta blocker users

1,228

739

489

1.51

1.05

1.44 (1.33-1.56)

Any high ceiling diuretic users

688

405

283

1.43

1.04

1.38 (1.23-1.53)

Sole high ceiling diuretic users

342

200

142

1.41

1.04

1.36 (1.14-1.57)

Combination: use of two subgroupsc

2,419

1,695

724

2.34

1.07

2.18 (2.10-2.27)

Combination: use of three or more subgroups

1,544

1,167

377

3.10

1.10

2.81 (2.69-2.93)

  1. ACEi angiotensin converting enzyme inhibitor, cSR crude sequence ratio, SRnull null-effect sequence ratio, aSR adjusted sequence ratio, 95% CI 95% confidence interval
  2. aAny users are patients that use other medication that can cause the same adverse drug reaction
  3. bSole users are patients that use NO other medication that can cause the same adverse drug reaction
  4. cCombination users are patients that use multiple medication that can cause the same adverse drug reaction
  5. Note: Combination users used any combination of subgroups (i.e., ACEi, beta blocker, high ceiling diuretics, low ceiling diuretics, calcium channel blockers, angiotensin II blockers, aldosterone antagonists and statins)